Study of radiation plus chemo and immunotherapy for rectal cancer
Part of Cancer clinical trials.
This trial tests a combination of radiation, chemotherapy (CAPOX), and immunotherapy (iparomlimab and tuvonralimab) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that is adenocarcinoma (the most common type).
- You are between 18 and 74 years old.
- You are in good general health (ECOG score 0 or 1).
- Your tumor is stage cT3-4N0M0 or TanyN1-2M0 and the bottom edge is within 10 cm of the anus.
- You have not had prior pelvic radiation or other cancer treatments in the last 4 weeks.
- Your heart, liver, kidney, and blood cell counts are adequate as checked by standard tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (regorafenib), and chemotherapy (CAPOX) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for people whose tumors have normal mismatch repair proteins (pMMR/MSS).
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests a combination of chemotherapy, targeted therapy, and immunotherapy, with or without radiation to the primary tumor, for people with advanced rectal cancer that has a specific genetic profile. It aims to see if adding radiation improves outcomes.
This trial tests a new combination of short-course radiation, an immunotherapy drug called ivonescimab, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.